A new trading day began on Tuesday, with NovoCure Ltd (NASDAQ: NVCR) stock price up 5.24% from the previous day of trading, before settling in for the closing price of $11.27. NVCR’s price has ranged from $10.70 to $34.13 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -83.87%. Meanwhile, its annual earnings per share averaged 10.10%. With a float of $99.52 million, this company’s outstanding shares have now reached $111.98 million.
NovoCure Ltd (NVCR) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Devices Industry. The insider ownership of NovoCure Ltd is 11.12%, while institutional ownership is 85.44%. The most recent insider transaction that took place on Sep 05 ’25, was worth 996,859. In this transaction Chief Executive Officer of this company bought 81,550 shares at a rate of $12.22, taking the stock ownership to the 437,569 shares. Before that another transaction happened on Jul 29 ’25, when Company’s Chief Financial Officer bought 20,000 for $11.59, making the entire transaction worth $231,800. This insider now owns 141,150 shares in total.
NovoCure Ltd (NVCR) Earnings and Forecasts
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.61 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 10.10% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 13.04% during the next five years compared to -83.87% drop over the previous five years of trading.
NovoCure Ltd (NASDAQ: NVCR) Trading Performance Indicators
Here are NovoCure Ltd’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.61, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -1.49 in one year’s time.
Technical Analysis of NovoCure Ltd (NVCR)
Looking closely at NovoCure Ltd (NASDAQ: NVCR), its last 5-days average volume was 2.26 million, which is a jump from its year-to-date volume of 1.32 million. As of the previous 9 days, the stock’s Stochastic %D was 18.47%.
During the past 100 days, NovoCure Ltd’s (NVCR) raw stochastic average was set at 14.50%, which indicates a significant decrease from 32.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.58 in the past 14 days, which was lower than the 0.64 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.04, while its 200-day Moving Average is $16.29. However, in the short run, NovoCure Ltd’s stock first resistance to watch stands at $12.19. Second resistance stands at $12.53. The third major resistance level sits at $13.05. If the price goes on to break the first support level at $11.34, it is likely to go to the next support level at $10.82. Should the price break the second support level, the third support level stands at $10.48.
NovoCure Ltd (NASDAQ: NVCR) Key Stats
With a market capitalization of 1.33 billion, the company has a total of 111,982K Shares Outstanding. Currently, annual sales are 605,220 K while annual income is -168,630 K. The company’s previous quarter sales were 167,200 K while its latest quarter income was -37,270 K.
